Last update 23 Oct 2025

LY-4066434

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
LY-4066434, LY4066434
Target
KRAS
Action
inhibitors
Mechanism
KRAS inhibitors(GTPase KRas inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]
Active Indication
Colorectal CancerLocally Advanced Malignant Solid NeoplasmMetastatic Solid Tumor+ [4]
Inactive Indication-
Originator Organization
Loxo Oncology, Inc.Loxo Oncology, Inc.
Active Organization
Eli Lilly & Co.Eli Lilly & Co.Lilly Research Center Ltd.Loxo Oncology, Inc.Loxo Oncology, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with LY-4066434
NCT06607185
/ RecruitingPhase 1
A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
100 Clinical Results associated with LY-4066434
Login to view more data
100 Translational Medicine associated with LY-4066434
Login to view more data
100 Patents (Medical) associated with LY-4066434
Login to view more data
100 Deals associated with LY-4066434
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colorectal CancerPhase 1
United States
Eli Lilly & Co.Eli Lilly & Co.
21 Oct 2024
Colorectal CancerPhase 1
China
Eli Lilly & Co.Eli Lilly & Co.
21 Oct 2024
Colorectal CancerPhase 1
Japan
Eli Lilly & Co.Eli Lilly & Co.
21 Oct 2024
Colorectal CancerPhase 1
Belgium
Eli Lilly & Co.Eli Lilly & Co.
21 Oct 2024
Colorectal CancerPhase 1
France
Eli Lilly & Co.Eli Lilly & Co.
21 Oct 2024
Colorectal CancerPhase 1
Germany
Eli Lilly & Co.Eli Lilly & Co.
21 Oct 2024
Colorectal CancerPhase 1
Italy
Eli Lilly & Co.Eli Lilly & Co.
21 Oct 2024
Colorectal CancerPhase 1
Spain
Eli Lilly & Co.Eli Lilly & Co.
21 Oct 2024
Colorectal CancerPhase 1
Taiwan Province
Eli Lilly & Co.Eli Lilly & Co.
21 Oct 2024
Locally Advanced Malignant Solid NeoplasmPhase 1
United States
Eli Lilly & Co.Eli Lilly & Co.
21 Oct 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free